These analyses suggested that co-expression of high levels of CD80 and PTK2 transcript occurs preferentially in cancer cell lines originating from patients with Burkitt’s Lymphoma, Hodgkin’s Lymphoma, Chronic Myeloid Leukemia, and Diffuse Large B-cell (DLBCL) Lymphoma. This evidence concerns the gene CD80 and Hodgkins lymphoma.